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ABSTRACT
Background. Centralization of pancreatic surgery in high-
volume hospitals is under debate in many countries. In the
western part of the Netherlands, the professional network
of surgical oncologists agreed to centralize all pancreatic
surgery from 2006 in two high-volume hospitals. Our aim
is to evaluate whether centralization of pancreatic surgery
has improved clinical outcomes and has changed referral
patterns.
Materials and Methods. Data of the Comprehensive
Cancer Centre West (CCCW) of all 249 patients who had a
resection for suspected pancreatic cancer between 1996
and 2008 in the western part of the Netherlands were
analyzed. Multivariable modeling was used to evaluate
survival for 3 time periods; 1996–2000, 2001–2005
(introduction of quality standards), and 2006–2008 (after
centralization). In addition, the differences in referral pat-
tern were analyzed.
Results. From 2006, all pancreatic surgery was centralized
in 2 hospitals. The 2-year survival rate increased after
centralization from 39% to 55% (P = .09) for all patients
who had a pancreatic resection for pancreatic cancer. After
adjustment for age, tumor location, stage, histology, and
adjuvant treatment, the latter period was signiﬁcantly
associated with improved survival (hazard ratio [HR] 0.50;
95% conﬁdence interval [95% CI] 0.34–0.73).
Conclusions. Centralization of pancreatic surgery was
successful and has resulted in improved clinical outcomes
in the western part of the Netherlands, demonstrating the
effectiveness of centralization.
In many countries, the question whether high-risk sur-
gery should be centralized in high-volume centers is
prominent in the quality of healthcare debate. The associ-
ation between high procedural volume and improved
outcomes is generally accepted, and the strongest associ-
ation is seen with high-risk, low volume procedures, such
as pancreatic or esophageal surgery.
1–8 Authors suggest
that especially these high-risk procedures can beneﬁt from
concentration in high-volume centers.
9 However, translat-
ing these results into practice is challenging.
In the Netherlands, the annual incidence of pancreatic
cancer is around 1700 new cases of pancreatic cancer and
around 440 cases of extra hepatic bile duct cancer (source:
Netherlands Cancer Registry). A resection is done in
approximately 15% of the cases, resulting in 300 pancreatic
resections for malignant disease each year. For more than a
decade, there is an ongoing debate for minimal volume
standards for pancreatic resections. However, despite the
plea for centralization, little had changed in referral pat-
terns or postoperative mortality in the period 1994–2004.
10
The Dutch Healthcare Inspectorate considers a minimal
volume standard for pancreatic resections, but already does
demand a minimal volume for esophageal resections.
Recently, Wouters et al. showed a reduction of postopera-
tive morbidity and length of stay after centralization of
esophageal resections in the Netherlands.
11 The postoper-
ative mortality fell from 12% to 4%. However, although
many studies on the volume outcome relationship for pan-
creatic surgery exist, reports showing actual improvement
of quality of care after centralization have only been scarce.
In the western part of the Netherlands, 9 hospitals are
afﬁliated with the Comprehensive Cancer Centre West
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country. In 2001 the professional network of surgical on-
cologists (PNSO) in the region formulated quality
standards for hospitals performing pancreatic surgery
(shown in the frame). Furthermore, they declared the
intention to centralize pancreatic surgery after a period of
monitoring. In 2005 the PNSO agreed to centralize all
pancreatic surgery in 2 centers from January 1, 2006.
In this study the outcomes of the centralization process in
the western part of the Netherlands are reported. Quality
criteria for pancreatic surgery formulated by the PNSO of
the CCCW in the Netherlands include: (1) new patients are
preoperatively and postoperatively discussed in a multidis-
ciplinary board with a gastroenterologist and a radiologist;
(2) all patients are operated on by an experienced surgeon;
(3) the hospital has an intensive care unit, intervention
radiology, and gastroenterology department; and (4) all
patients are operated on by two surgeons together.
METHODS
Hospitals and Centralization
From 1996 until 2005 the CCCW had 11 afﬁliated
hospitals. After 2 mergers in 2006, 9 afﬁliated hospitals
were left: 1 academic center, 6 teaching hospitals, and 2
nonteaching hospitals. All are located in the midwestern
part of the Netherlands and fully cover the region west.
This area is mainly urban with 1.7 million inhabitants.
Traveling distances between hospitals are 45 km (30 miles)
maximum.
From 1996 until 2005 all hospitals performed pancreatic
surgery. Since 2006 pancreatic surgery was centralized in 2
hospitals: the Leiden University Medical Centre (LUMC),
an academic center, and the Reinier de Graaf Hospital
(RdGG), a teaching hospital.
Data Source
In the Netherlands, the nationwide population based
Netherlands Cancer Registry (NCR) registers all newly
diagnosed malignancies. Independently trained data man-
agers from the NCR collect data from original patient ﬁles,
after receiving an automatic report from the Dutch pathol-
ogy reporting system PALGA. Completeness of the cancer
registry is cross-checked by linking with the Dutch National
Registry of Hospital Discharge Diagnosis, which is a near-
complete registry of hospital discharge data for all in-hos-
pital treatments. Information on patient characteristics,
tumor characteristics, treatment, hospital of diagnosis,
hospital of treatment, and follow-up is recorded. For coding
tumor site and morphology the International Classiﬁcation
of Diseases for Oncology (ICD-0) is used.
12 Cancers are
staged according the TNM classiﬁcation (TNM classiﬁca-
tion of Malignant Tumors, 6th edition).
13 The quality of the
data is high, and completeness is estimated to be at least
95%.
14 Vital status of all patients was obtained actively on a
regular basis through linkage of the cancer registry data
with the integrated database of the municipal registry.
The Leiden cancer registry (part of the NCR), collects
data of all patients who are diagnosed for a new malig-
nancy in 1 of the afﬁliated hospitals in the CCCW region.
All hospitals gave formal consent to participate.
In addition, after centralization, operating surgeons
register all patients who undergo pancreatic surgery (both
for malignant and benign diagnoses) in an electronically
shared database to monitor the results. Completeness of the
data was further cross-checked with linking of the shared
database to the cancer registry.
Patient Groups
Patients with pancreatic surgery for cancer in the region
of the CCCW from January 1, 1996 to December 31, 2008
were identiﬁed from the NCR, which covered surgically
treated malignancies of pancreas (C25), duodenum
(C17.0), ampulla of Vater (C24.1), and the hepatic bile
duct (C24.0). Patient demographics, pathological notes,
TNM staging, and data on surgical and (neo-) adjuvant
treatments were collected.
Additional data on comorbidities, detailed postoperative
complications, length of stay, and margin status of all
patients who underwent pancreatic surgery between 2006
and 2008 for both malignant and benign diagnoses were
collected from the shared database.
Outcomes
Outcomes of pancreatic resections in 3 time periods
were compared: 1996–2000, 2001–2005, and 2006–2008.
In the ﬁrst period from 1996 till 2000, no quality control
for pancreatic surgery was performed in the region. In
2001, quality standards were implemented and from 2006
pancreatic surgery was centralized in 2 hospitals. Outcome
was assessed using 30-day mortality, 90-day survival, 1-
year survival, and 2-year survival and the number of
evaluated lymph nodes. Survival was calculated as the
difference between date of surgery, or—if not available—
the date of conﬁrmed diagnosis (which is usually the same
as the date of surgery), and, either the date of death, or the
date of last patient follow-up. Follow-up of patients was
completed until January 1, 2010.
For the period 2006–2008, postoperative complications,
length of stay, length of ICU admission, and margin status
were also analyzed.
1822 G. A. Gooiker et al.Statistical Methods
Descriptive statistics were calculated for all variables.
Differences in patient, tumor, and treatment characteristics
between the 3 time periods as well as outcome measure-
ments were assessed using the Kruskal–Wallis test (for
continuous variables) and chi-square test (for categorical
variables).
Observed survival rates were estimated with the Kap-
lan–Meier method. Differences in survival between the 3
time periods were assessed with the log-rank test. The
multivariate Cox proportional hazard model was used to
identify factors associated with improved survival after
surgery. Period of diagnosis, age, tumor location, histol-
ogy, stage, and adjuvant chemotherapy and radiotherapy
were entered in the multivariate model as prognostic fac-
tors. All analyses were conducted with SPSS version 15
(SPSSinc, Chicago, IL).
RESULTS
Centralization and Referral Pattern
From 1996 until 2005 pancreatic surgery was performed
in all CCCW-afﬁliated hospitals. The mean annual hospital
volume of oncologic pancreatic resections was 1.7 in
1996–2000 and 2.0 in 2001–2005. Since January 1, 2006,
all pancreatic surgery was centralized in 2 hospitals. The
mean annual hospital volume increased to 23.
After centralization, the percentage of patients receiving
surgical treatment for pancreatic cancer, increased from
14.3% to 18.4% (P = .08). The proportion of patients who
are living in the CCCW region and had surgery within the
region increased from 55% to 69% (P = .085).
Characteristics and Crude Outcomes
Table 1 shows the characteristics of 249 patients who
underwent pancreatic surgery for a malignancy from 1996
to 2008 in the CCCW region, stratiﬁed by the period of
diagnosis. There were no signiﬁcant differences in patient
age, tumor stage, and histology. In the latter period, more
patients had a tumor located in the pancreas and chemo-
therapy use increased from 2.4% in 1996–2000, to 23.6%
in 2006–2008.
Table 2 shows the crude outcomes. The 30-day mor-
tality fell from 8% in the ﬁrst period to 0% and 2% in the
latter periods. Testing of statistical signiﬁcance was not
feasible because of low numbers. Of all patients with a
malignant tumor, the observed 90-day survival improved
from 88% to 96% (P = .03), and the 2-year survival from
39% to 55% (P = .09). The 2-year survival ﬁrst dropped
from 38% to 28% in the ﬁrst two time periods and then
improved to 49% in the latest period (P = .04).
The median number of evaluated lymph nodes increased
signiﬁcantly from median 2 to median 7 lymph nodes
examined.
There was no signiﬁcant change in observed overall
survival (P = .106, Fig. 1).
Univariate and Multivariate Analysis of Survival
In univariate analysis, risk of death was associated with
higher age, a tumor located in the pancreas, stage III and
IV, adenocarcinoma of the pancreas, and diagnosis in the
early periods (Table 3).
After adjustment for age, tumor location, histology,
stage, and adjuvant therapy, a signiﬁcant association
between the latest period of diagnosis and a lower risk of
death was seen (hazard ratio [HR] 0.50; 95% conﬁdence
interval [95% CI] 0.34–0.73).
Figure 2 shows that after risk adjustment patients diag-
nosed in the latest period had a signiﬁcantly better survival
compared with patients diagnosed before centralization.
Additional Characteristics and Outcomes 2006–2009
In the period 2006–2009, in total 213 patients underwent
pancreatic surgery in the 2 high-volume hospitals. Almost
25% of all pancreatic surgery was done for benign diag-
nosis (53 of 213). Most patients had comorbidity (63%)
and were classiﬁed as ASA II (62%) or higher (15%). The
Whipple and the PPPD procedure were the most performed
procedures (49%).
The postoperative mortality was 3.3% (7 of 213) and
38% (82 of 213) had postoperative complications. Rein-
tervention was carried out in (18 of 213) 8.6% of all
patients. The median length of stay was 10 days, and the
median stay at the ICU was 1 day. The median interval
between ﬁrst contact and surgery was 22 days. Of all
patients who had pancreatic surgery for a malignant diag-
nosis, 115 of 160 (72%) had tumor-free margins (R0), 29 of
160 (18%) had microscopic margin involvement (R1), and
1 patient had macroscopic margin involvement (R2). From
15 of 160 (10%) the margin status was unknown.
DISCUSSION
The present study shows that after centralization of
pancreatic surgery, the survival of patients with pancreatic
malignancies actually improved. After adjusting for dif-
ferences in age, tumor stage, location, histology, and
adjuvant treatment, a strong association between surgery
after centralization and improved survival was shown (HR
Centralization of Pancreatic Surgery 18230.50; 95% CI 0.34–0.73). In addition, after centralization a
higher proportion of patients with pancreatic cancer
received surgery.
To date there are 9 studies, reporting the association of
concentration of pancreatic care and clinical outcomes
(Table 4).
15–23 Most did not evaluate centralization as an
intervention, but described the concentration of care over
time. All studies were based on large administrative dat-
abases. In-hospital mortality was the outcome parameter in
all studies, and only 4 were risk adjusted. None provided
information on survival.
Most previous studies showed a beneﬁcial effect of
centralization on in-hospital mortality with mortality
reductions varying from 12% to 0.5%. Rosemurgy et al.
observed an increased mortality, despite fewer surgeons
carried out more pancreatic resections.
21 This was attrib-
uted to the fact that most pancreatic surgery was still done
by low-volume surgeons and the mortality rate for surgeons
in the lowest volume category increased signiﬁcantly.
This study shows that centralization in the CCCW
region was successful. The centralization was based on
regional agreement; thus, the regional availability of sur-
gical care was ensured. A frequently mentioned argument
against centralization is the concern that the travel burden
is too demanding for patients and their family.
24 Our
results show an increase of patients operated on within
their own region. However, travel distances between the
nine afﬁliated hospitals did not exceed 45 km, so the
beneﬁt is limited.
The increased burden of pancreatic surgery in the 2
centers did not result in increased waiting times.
The percentage of patients who received surgical treat-
ment for pancreatic cancer increased from 14% to 18%.
Because surgical treatment remains the only potential for
curing pancreatic cancer, this can potentially beneﬁt the
survival of more patients.
The additional outcomes from the period 2006–2009 of
all pancreatic surgery were comparable to reported out-
comes of other high-volume centers. The number of
evaluated lymph nodes increased signiﬁcantly (from med-
ian 2 to median 7 examined lymph nodes).
25 The
complication rate and the rate of involved margins were
acceptable and comparable to previously described
rates.
26,27 The median length of stay of 10 days, is shorter
than previously reported.
28
The present study has several strengths. The NCR pro-
vides clinical, population-based data, which are reliable
and complete. In addition, a multivariate analysis was
TABLE 1 Characteristics of
249 patients with pancreatic
surgery for a malignancy in the
western part of the Netherlands
between 1996 and 2008
a Other histology includes
(neuro)endocrine tumors,
carcinoid tumors, and
unspeciﬁed histology
1996–2000 N (%) 2001–2005 N (%) 2006–2008 N (%) P value
Total No. of patients 85 89 110
Gender
Male 40 (47.1) 48 (53.9) 52 (47.3) .572
Female 45 (52.9) 41 (46.1) 58 (52.7)
Age
\50 years 13 (15.3) 16 (18.0) 9 (8.2) .218
50–74 years 60 (70.6) 64 (71.9) 82 (74.5)
C75 years 12 (14.1) 9 (10.1) 19 (17.3)
Tumor location
Pancreas 45 (52.9) 60 (67.4) 78 (70.9) .046
Extrahepatic bile duct 29 (34.1) 16 (18.0) 22 (20.0)
Duodenum 11 (12.9) 13 (14.6) 10 (9.1)
Histology
Adenocarcinoma 72 (84.7) 71 (79.8) 98 (89.1) .190
Other
a 13 (15.3) 18 (20.2) 12 (10.9)
Stage (pTNM)
I–II 41 (48.2) 38 (42.7) 40 (36.4) .073
III–IV 33 (38.8) 31 (34.8) 56 (50.9)
Other 11 (12.9) 20 (22.5) 14 (12.7)
Chemotherapy
Yes 2 (2.4) 5 (5.6) 26 (23.6) .000
No 83 (97.6) 84 (94.4) 84 (76.4)
Radiotherapy
Yes 5 (5.9) 3 (3.4) 0
No 80 (94.1) 86 (96.6) 110 (100)
1824 G. A. Gooiker et al.performed to adjust for confounding factors, which could
be responsible for the improved survival after centraliza-
tion. However, also several limitations to our data exist.
First, the cancer registration only collects data of
malignant diagnosis. However, pancreatic surgery for
benign pathology does contribute to the experience of the
surgeon and the hospital. In the latest period, pancreatic
surgery was performed in 25% of the cases because of
benign diagnoses. It is expected that including benign
diagnosis could have had an additional effect on the effect
of centralization.
In addition, we had no data on comorbid diseases until
2006. Consequently, risk adjustment for comorbidity, an
important determinant of clinical outcome, was not possi-
ble.
29 Differences in comorbidity could have inﬂuenced
our results. In the latest period, 64% of all patients had
comorbid disease and the majority was classiﬁed as ASA II
or higher. We expect that this was not higher in the pre-
vious periods because no increase of age occurred and
therefore will not have inﬂuenced the survival analysis.
Also, we had no detailed information about structural
changes in the management of pancreatic cancer. After
centralization, a higher proportion of patients received
chemotherapy, which could have explained the better sur-
vival. However, the univariate and multivariate analysis
did not show a signiﬁcant effect of chemotherapy. We
expect that since centralization, more patients who had
tumor invasion in the venal portal wall had more extensive
resections, including resection of the vessel wall. However,
this improvement can be attributed to the centralization:
more experienced surgeons could also have more experi-
ence with more extensive resections.
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FIG. 1 Observed survival after pancreatic surgery for malignant
diagnosis, for the periods 1996–2000, 2001–2005, and 2006–2008
(calculated with log-rank test; P = .106)
Centralization of Pancreatic Surgery 1825Awareness on quality assurance could have had an
intrinsic effect on the practice patterns and the dedication
of the surgeons and thus have impact on the quality of care,
which is known as the Hawthorne effect.
30 However,
quality standards were already introduced in 2001 and no
differences were detected between the ﬁrst period and the
period after the quality initiatives were started.
The improved survival can also be explained by better
patient selection for surgery. In the last period the resection
rate increased and the majority of the resected patients was
classiﬁed as ASA II or higher. The primary tumor was
more often located in the pancreas and the extrahepatic bile
ducts and less in the duodenum. This suggests that more
patients were eligible for a resection after centralization.
At last, the improved survival could have been the result
of other improvements in the diagnosis, surgical technique,
or postoperative care. However, at a national level, no
improvement in overall survival of pancreatic cancer during
our study period was observed in the Netherlands (source:
Netherlands Cancer Registry, available at www.ikcnet.nl).
TABLE 3 Univariate and
multivariate Cox regression
analysis of overall survival in
n = 274 patients with
pancreatic surgery following
diagnosis of cancer in pancreas,
ampulla of Vater, extrahepatic
bile duct, or duodenum. The risk
of dying is presented as hazard
ratio (HR) with the 95%
conﬁdence interval (95% CI)
Characteristics Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Period of diagnosis .11 .001
1996–2000 1 – 1 –
2001–2005 0.79 0.56–1.11 0.94 0.67–1.33
2006–2007 0.69 0.49–0.98 0.50 0.34–0.73
Age .008 .17
\50 years 1 – 1 –
50–74 years 2.13 1.32–3.44 1.49 0.90–2.46
C75 years 1.99 1.11–3.58 1.76 0.96–3.22
Gender .84
Male 1 –
Female 1.03 0.78–1.36
Tumor location \.0001 \.0001
Pancreas (C25) 1 – 1 –
Other (C24, C17.1) 0.52 0.38–0.71 0.48 0.35–0.67
Histology \.0001 .001
Adenocarcinoma 1 – 1 –
Other 0.29 0.18–0.49 0.31 0.15–0.61
Stage (pTNM) \.0001 \.0001
I–II 1 – 1 –
III–IV 2.26 1.65–3.08 2.46 1.78–3.42
Unknown/no TNM 0.60 0.37–0.99 1.38 0.73–2.60
Chemotherapy .42 .81
N o 1– 1–
Yes 1.20 0.77–1.86 1.07 0.63–1.80
Radiotherapy .09 .76
N o 1– 1–
Yes 1.84 0.91–3.73 1.14 0.50–2.59
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FIG. 2 Survival curves for patients with pancreatic surgery for a
malignant diagnosis, after adjustment for age, tumor location,
histology, and stage, in the western part of the Netherlands, for the
periods 1996–2000, 2001–2005, and 2006–2008
1826 G. A. Gooiker et al.Although this includes both resected and unresected
patients, it can be expected that general improvements in
the management of pancreatic cancer would have led to an
improved survival at a national level. Nevertheless, pro-
gress in techniques could have interfered with our ﬁndings.
It is suggested that the beneﬁcial effect of centralization
can be explained by better facilities in high-volume centers
and more experience of the surgical team, leading to fewer
complications, and better treatment adjusted to the
patient.
31 These facilities include specialized diagnostic
procedures, anesthetic and postoperative care, radiologic
and endoscopic interventions, early recognition and treat-
ment of complications, multidisciplinary teams, knowledge
of nutrition, and so forth. It is challenging to identify
essential structural characteristics for good quality.
32
Bilimoria showed differences in the utilization of multim-
odality therapy between low- and high-volume providers.
33
Patients with localized pancreatic cancer were more likely
to receive pancreatectomy and adjuvant chemoradiation at
academic and high-volume centers. This suggests that more
frequent use of surgery and chemoradiation may be one of
the underlying reasons of improved outcomes in high-vol-
ume centers. Our data show an increased utilization of
surgery and adjuvant chemotherapy after centralization as
well. Nevertheless, after adjusting for adjuvant chemo-
therapy, survival was still higher after centralization.
Volume Standards
The evidence for better outcome of complex, low-vol-
ume surgical procedures in high-volume centers and the
large disparities in quality of care between high- and low-
volume centers have fueled the discussion about central-
ization. Volume is considered a proxy for high quality of
care, and volume standards are recommended to improve
patient outcomes. However, a minimum volume standard
cannot be identiﬁed.
In the region of the CCCW in the Netherlands, cen-
tralization was based on mutual agreement to assign each
complex, low-volume procedure to a different afﬁliated
hospital. The pancreatic procedures were centralized in 2
hospitals with proven high quality of care and the required
facilities to perform pancreatic surgery. In this way, the
availability of good care in the region was ensured. This
can be an example for future centralization initiatives.
However, bottom-up centralization initiatives are lack-
ing. Despite the plea for centralization, the referral patterns
did not change in the Netherlands in the period 1994–2003,
TABLE 4 Outcomes reported in previous studies evaluating centralization of pancreatic surgery
Author Year Country Unit Period % HVH No. hospitals/
surgeons
c
Inhospital
mortality
P value OR (CI) RR (CI)
Gordon
15 1998 USA Hospital 1984 21 17.2 1
1995
a 59 4.9 0.92 (0.86–0.99)
Ho
16 2006 USA Hospital 1988–1991 2.6
b 11.4 1
1992–1996 3.1
b 10.0 0.97 (0.76–1.23)
1997–2000 4
b 8.3 0.91 (0.71–1.17)
Riall
17 2007 USA Hospital 1999 54.5 6.6 .01
2004
a 63.3 3.9
McPhee
18 2007 USA Hospital 1988 30 7.8 1.49 (1.04–2.13)
2003
a 39 4.6 1
Langer
19 2007 Canada Hospital 1988–1996 18 72 10.2
2002–2004 61 28 4.5 Not reported
Pal
20 2008 UK Hospital 1999–2002 101 6.2
2002–2005 73 5.7 Not reported
Rosemurgy
21 2008 USA Surgeon 1995–1997 266 5.1
2003–2005 282 5.9 .45
Stitzenberg
22 2009 USA Hospital 1996 35 7.3
2006
a 70 3.8 .001
Gasper
23 2009 USA Hospitals 1990–1994 28 9.9
1995–1999 37 7.1
2000–2004 58 6.0 Not signiﬁcant
a Not two separate periods compared but a gradual trend over time between the 2 noted years
b Mean annual hospital volume
c No. of hospitals or surgeons performing pancreatic surgery
Centralization of Pancreatic Surgery 1827and only slight changes were seen in the United States in
the period 1998–2003.
10,18 Therefore, a top-down intro-
duction of minimal volume standards might be necessary to
improve the outcomes of pancreatic surgery. In the United
States, the Leapfrog Group, a coalition of large employers
and public and private purchasers of health care, introduced
a volume standard for pancreatic resections of 11 proce-
dures per year.
34 In Europe, minimal volume standards are
currently under consideration.
In conclusion, our study shows that centralization has
resulted in improved clinical outcomes of patients who
underwent pancreatic surgery for a malignancy. Central-
ization was realized by agreement of the regional network
of surgical oncologists and did not require major structural
changes in organization, nor did it affect the accessibility
of the health care. These results are encouraging and show
how centralization initiatives can actually improve quality
of care in a straightforward way. Since regional central-
ization initiatives are lacking, a top-down introduction of
minimal volume standards might be an effective approach
to improve the quality of care.
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